Xtant Medical Holdings Inc
XTNT0.795USD
+0.025+3.26%
Market hours （ET）Quotes delayed by 15 min
111.32MMarket Cap
61.45P/E TTM
More Details of Xtant Medical Holdings Inc Company
Xtant Medical Holdings, Inc. is a global medical technology company. The Company is focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Its biomaterial products include OsteoSponge, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, OsteoVive, OsteoFactor, line of 3Demin products, as well as other allografts. It offers a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor. Its key spinal implant product lines include Cervical products, Thoracolumbar products, Sacroiliac Joint products, Interbody products and Interlaminar Stabilization products.
Xtant Medical Holdings Inc Info
Ticker SymbolXTNT
Company nameXtant Medical Holdings Inc
IPO dateJun 30, 2010
CEOBrowne (Sean E)
Number of employees217
Security typeOrdinary Share
Fiscal year-endJun 30
Address664 Cruiser Lane
CityBELGRADE
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code59714
Phone14063880480
Websitehttps://xtantmedical.com/
Ticker SymbolXTNT
IPO dateJun 30, 2010
CEOBrowne (Sean E)
Company Executives of Xtant Medical Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Stavros G. Vizirgianakis
Mr. Stavros G. Vizirgianakis
Independent Chairman of the Board
Independent Chairman of the Board
7.52M
+7.95%
Mr. John K. Bakewell
Mr. John K. Bakewell
Independent Director
Independent Director
1.07M
+41.87%
Mr. Robert E. Mcnamara
Mr. Robert E. Mcnamara
Independent Director
Independent Director
591.99K
-2.79%
Mr. Scott C. Neils
Mr. Scott C. Neils
Chief Financial Officer
Chief Financial Officer
575.01K
+84.46%
Mr. Abhinav (Abi) Jain
Mr. Abhinav (Abi) Jain
Director
Director
158.23K
--
Ms. Lori D. Mitchell-Keller
Ms. Lori D. Mitchell-Keller
Independent Director
Independent Director
--
--
Mr. Tyler P. Lipschultz
Mr. Tyler P. Lipschultz
Director
Director
--
--
Mr. Sean E. Browne
Mr. Sean E. Browne
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Mark A. Schallenberger
Mr. Mark A. Schallenberger
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Jonn R. Beeson
Mr. Jonn R. Beeson
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Stavros G. Vizirgianakis
Mr. Stavros G. Vizirgianakis
Independent Chairman of the Board
Independent Chairman of the Board
7.52M
+7.95%
Mr. John K. Bakewell
Mr. John K. Bakewell
Independent Director
Independent Director
1.07M
+41.87%
Mr. Robert E. Mcnamara
Mr. Robert E. Mcnamara
Independent Director
Independent Director
591.99K
-2.79%
Mr. Scott C. Neils
Mr. Scott C. Neils
Chief Financial Officer
Chief Financial Officer
575.01K
+84.46%
Mr. Abhinav (Abi) Jain
Mr. Abhinav (Abi) Jain
Director
Director
158.23K
--
Ms. Lori D. Mitchell-Keller
Ms. Lori D. Mitchell-Keller
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Orthobiologics
19.37M
54.70%
Spinal implant
11.07M
31.25%
License revenue
4.97M
14.05%
By RegionUSD
Name
Revenue
Proportion
United States
32.13M
90.74%
Rest of World
3.28M
9.26%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Orthobiologics
19.37M
54.70%
Spinal implant
11.07M
31.25%
License revenue
4.97M
14.05%
Shareholding Stats
Updated: Sat, Nov 22
Updated: Sat, Nov 22
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Nantahala Capital Management, LLC
48.85%
Lytton (Laurence W)
6.76%
Vizirgianakis (Stavros G)
5.37%
AWM Investment Company, Inc.
4.71%
The Vanguard Group, Inc.
1.68%
Other
32.63%
Shareholders
Shareholders
Proportion
Nantahala Capital Management, LLC
48.85%
Lytton (Laurence W)
6.76%
Vizirgianakis (Stavros G)
5.37%
AWM Investment Company, Inc.
4.71%
The Vanguard Group, Inc.
1.68%
Other
32.63%
Shareholder Types
Shareholders
Proportion
Hedge Fund
49.59%
Individual Investor
16.56%
Investment Advisor/Hedge Fund
5.20%
Investment Advisor
2.37%
Research Firm
0.04%
Other
26.23%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
58
80.07M
57.19%
-75.11M
2025Q2
66
93.42M
67.06%
-16.04M
2025Q1
66
107.33M
77.15%
-2.25M
2024Q4
65
107.45M
77.30%
-1.32M
2024Q3
60
109.08M
78.63%
+8.43M
2024Q2
61
99.68M
76.50%
-1.69M
2024Q1
63
100.56M
77.45%
+777.79K
2023Q4
59
100.17M
77.23%
+1.05M
2023Q3
55
100.31M
77.56%
+9.94M
2023Q2
49
90.55M
83.28%
+1.27M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Nantahala Capital Management, LLC
68.39M
48.85%
--
--
Aug 01, 2025
Lytton (Laurence W)
9.46M
6.76%
+9.46M
--
Apr 15, 2025
Vizirgianakis (Stavros G)
6.96M
4.97%
+748.65K
+12.05%
Sep 09, 2025
AWM Investment Company, Inc.
6.60M
4.71%
+6.60M
--
Jun 30, 2025
The Vanguard Group, Inc.
2.25M
1.61%
--
--
Jun 30, 2025
Browne (Sean E.)
1.54M
1.1%
+43.55K
+2.90%
Sep 09, 2025
Beeson (Jonn R.)
1.37M
0.98%
+162.16K
+13.37%
Sep 09, 2025
Bakewell (John K)
755.89K
0.54%
+162.16K
+27.31%
Sep 09, 2025
Renaissance Technologies LLC
650.71K
0.46%
-60.50K
-8.51%
Jun 30, 2025
Neils (Scott C)
311.72K
0.22%
+111.54K
+55.72%
Sep 09, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Xtant Medical Holdings Inc?
The top five shareholders of Xtant Medical Holdings Inc are:
Nantahala Capital Management, LLC holds 68.39M shares, accounting for 48.85% of the total shares.
Lytton (Laurence W) holds 9.46M shares, accounting for 6.76% of the total shares.
Vizirgianakis (Stavros G) holds 6.96M shares, accounting for 4.97% of the total shares.
AWM Investment Company, Inc. holds 6.60M shares, accounting for 4.71% of the total shares.
The Vanguard Group, Inc. holds 2.25M shares, accounting for 1.61% of the total shares.
Nantahala Capital Management, LLC holds 68.39M shares, accounting for 48.85% of the total shares.
Lytton (Laurence W) holds 9.46M shares, accounting for 6.76% of the total shares.
Vizirgianakis (Stavros G) holds 6.96M shares, accounting for 4.97% of the total shares.
AWM Investment Company, Inc. holds 6.60M shares, accounting for 4.71% of the total shares.
The Vanguard Group, Inc. holds 2.25M shares, accounting for 1.61% of the total shares.
What are the top three shareholder types of Xtant Medical Holdings Inc?
The top three shareholder types of Xtant Medical Holdings Inc are:
Nantahala Capital Management, LLC
Lytton (Laurence W)
Vizirgianakis (Stavros G)
Nantahala Capital Management, LLC
Lytton (Laurence W)
Vizirgianakis (Stavros G)
How many institutions hold shares of Xtant Medical Holdings Inc (XTNT)?
As of 2025Q3, 58 institutions hold shares of Xtant Medical Holdings Inc, with a combined market value of approximately 80.07M, accounting for 57.19% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -9.87%.
What is the biggest source of revenue for Xtant Medical Holdings Inc?
In FY2025Q2, the Orthobiologics business generated the highest revenue for Xtant Medical Holdings Inc, amounting to 19.37M and accounting for 54.70% of total revenue.
